Amblyopia is the leading cause of monocular visual impairment in children and adults. Despite
conventional treatment with patching or eye drops, many older children and adults do not
achieve normal vision in the amblyopic eye.
Donepezil is an acetylcholinesterase inhibitor that increases levels of the neurotransmitter
acetylcholine in the brain. Use of acetylcholinesterase inhibitors has been demonstrated by
the Hensch lab (Department of Neurology, FM Kirby Neurobiology Center) at Boston Children's
Hospital to improve vision and reverse amblyopia in animal models.
The purpose of this study is to evaluate the efficacy of oral donepezil as treatment for
residual amblyopia (20/50 - 20/400) in patients 8 years of age and older.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital